Zepbound Outperforms CagriSema in Head to Head Phase III Obesity Trial Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Current Obesity Reports Springer Nature Link EASD 2023: meta analysis shows tirzepatide superiority to semaglutide Clinical Trials Arena Tirzepatide vs. Semaglutide: Which Weight Loss Medication is Right for You? BodyByBariatrics